Indication
Chronic hepatitis B
Chronic hepatitis B is a persistent infection of the liver caused by the hepatitis B virus (HBV), serologically defined by the presence of hepatitis B surface antigen (HBsAg) in the blood for at least six months. Read more about Chronic hepatitis B
53 drugs 38 manufacturers
Drugs that treat it
Common Chronic hepatitis B therapies.
INTRON A (interferon alfa-2b,recomb.)
INTRON A (interferon alfa-2b,recomb.)
INTRON A (interferon alfa-2b,recomb.)
ADEFOVIR DIPIVOXIL
ENTECAVIR
ENTECAVIR
ENTECAVIR
ENTECAVIR
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic hepatitis B is a persistent infection of the liver caused by the hepatitis B virus (HBV), serologically defined by the presence of hepatitis B surface antigen (HBsAg) in the blood for at least six months.
Pathophysiologically, the viral genome establishes covalently closed circular DNA (cccDNA) within host hepatocytes, where host immune-mediated responses rather than direct viral cytopathology drive hepatic necroinflammation.
The condition encompasses a dynamic clinical spectrum ranging from asymptomatic, inactive carrier states to active hepatitis marked by elevated serum alanine aminotransferase and circulating HBV DNA.
Left untreated, progressive chronic necroinflammation significantly elevates the risk of severe hepatic complications, including progressive fibrosis, cirrhosis, hepatic decompensation, and hepatocellular carcinoma.
- cdc.gov
Chronic hepatitis B is a persistent infection of the liver caused by the hepatitis B virus (HBV), serologically defined by the presence of hepatitis B surface antigen (HBsAg) in the blood for at least six months
- nih.gov
Chronic hepatitis B is a persistent infection of the liver caused by the hepatitis B virus (HBV), serologically defined by the presence of hepatitis B surface antigen (HBsAg) in the blood for at least six months The condition encompasses a dynamic clinical spectrum ranging from asymptomatic, inactive carrier states to active hepatitis marked by elevated serum alanine aminotransferase and circulating HBV DNA Left untreated, progressive chronic necroinflammation significantly elevates the risk of ...
- nih.gov
Pathophysiologically, the viral genome establishes covalently closed circular DNA (cccDNA) within host hepatocytes, where host immune-mediated responses rather than direct viral cytopathology drive hepatic necroinflammation
- nih.gov
Pathophysiologically, the viral genome establishes covalently closed circular DNA (cccDNA) within host hepatocytes, where host immune-mediated responses rather than direct viral cytopathology drive hepatic necroinflammation
- aasld.org
The condition encompasses a dynamic clinical spectrum ranging from asymptomatic, inactive carrier states to active hepatitis marked by elevated serum alanine aminotransferase and circulating HBV DNA
- cdc.gov
Left untreated, progressive chronic necroinflammation significantly elevates the risk of severe hepatic complications, including progressive fibrosis, cirrhosis, hepatic decompensation, and hepatocellular carcinoma
Personalize your experience
Follow Chronic hepatitis B and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.